Profit

FY14 looks solid, too early to give guidance: Sun Pharma

PUBLISHED ON: April 10, 2013 | Duration: 4 min, 43 sec

facebooktwitteremailkoo
loading..
Uday Baldota, Senior Vice President, Finance and Accounts at Sun Pharma, feels that FY14 will be a steady growth year with lots of big revenue opportunities. He talks about the 100 pending approvals from the US drug regulator, and also gives some idea about a potential acquisition.
ALSO WATCH
Moderna Approved For Emergency Use, 4th Vaccine Okayed By India

................................ Advertisement ................................

................................ Advertisement ................................

Listen to the latest songs, only on JioSaavn.com